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1. Introduction 
Mother and child are genetically different and the 
fetus could be looked upon as an allograft. The reason 
why this allograft is accepted isunknown. A physio- 
logical barrier between mother and fetus [ 1 ], and the 
presence of blocking antibodies [2] and hormones [3] 
have been suggested. A depression of the maternal cell- 
mediated immune reactivity [4-6] is another explana- 
tion supported by the report of Kasakura [7] that ma- 
ternal plasma during pregnancy suppressed the mixed 
leucocyte reaction. 
The concentration i  plasma of many proteins is 
altered uring pregnancy but some proteins are pro- 
duced in extensively increased amounts. The pregnan- 
cy zone protein (PZ) [8-16] is an a2-globulin which 
is absent or present in only small amounts in the sera 
of non-pregnant women. During pregnancy the serum 
level of this globulin is increased in most women from 
0-4  rag/100 ml to values between 50-200 mg/100 
ml. The maximum is generally reached in the third tri- 
mester and after delivery there is a rapid decrease to 
normal evels [ 17]. In women with early spontaneous 
abortion PZ is found rarely or in small amounts [18]. 
The PZ protein has been isolated and found to have 
a mol. wt. of 326 000 [19]. 
In the present study PZ was found to inhibit the 
phytohaemagglutinin (PHA)-induced lymphocyte stim- 
ulation, believed to be an in vitro correlate of cell- 
mediated immunity. 
2. Materials and methods 
PZ was isolated as described earlier [19]. Serum 
samples were obtained from pregnant women and the 
amounts of PZ were measured by single radial immuno- 
diffusion [ 17]. 
Venous blood was obtained from healthy non-preg- 
nant blood donors. Lymphocytes were prepared from 
300 ml blood by filtration through a nylon fibre col- 
umn [20, 21] followed by sedimentation in glass tubes 
placed at an angle of 45 ° for 1 hr at room tempera- 
ture. The supernatant fluid was collected and centri- 
fuged at 500g for 10 min. 
The resulting cell pellet was resuspended in a syn- 
thetic medium 199:HEPES [22] and cultures were 
established in Microtest II-tissue culture plates (Falcon 
Plastics, Los Angeles, California), each culture contain- 
ing 0.2 million lymphocytes. 
In one experiment serum samples from ten preg- 
nant women with more than 100 mg pregnancy zone 
protein per 100 ml of serum were compared to serum 
samples from eight pregnant women with less than 
4 mg per 100 ml of serum. Each culture contained 
100/al of 199:HEPES and 70/al of the serum sample 
to be tested. Every individual serum sample was 
tested in duplicate and the results were expressed as 
the mean of the two measurements. 
In a second experiment the purified pregnancy 
zone protein was tested. Each culture contained 80/.d 
of 199:HEPES and 20/zl of autologous plasma. Each 
culture also contained 70 #1 of either: a) saline only 
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Fig. 1. The lymphocyte r sponse to PHA with sera from ten 
women with more than 100 mg per 100 ml of PZ and in eight 
women with less than 4 mg per 100 ml. The incorporation of 
[3H] thymidine into DNA was measured. 
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Fig. 2. The lymphocyte r sponse to PHA with 70/~1 samples 
of 1) saline 2) bovine albumin (0.55 mg/ml) 3) bovine albu- 
min (0.22 mg/ml) and 4) purified PZ protein (0.22 mg/ml). 
The incorporation of [~H]thymidine into DNA was measured. 
3. Results 
(0.9% NaC1); b) bovine albumin in saline to a final 
concentration of 0.55 mg/ml; c) bovine albumin in 
saline to a final concentration of 0.22 mg/ml or 
d) pregnancy zone protein in saline to a final concen- 
tration of 0.22 mg/ml. Cultures were established in 
triplicate. 
After 2 hr at 37°C 2/ag PHA (Bacto-phytohaemag- 
glutinin P, Difco Laboratories, Detroit, Michigan) in 
30 ~1 saline were added to each culture. The cultures 
were incubated for 62 hr at 37°C in humidified air sup- 
plemented with 5% (v/v) CO 2. Five hours before the 
end of the culture period 0.4/aCi of [3H]thymidine 
(specific activity 2.0 Ci/mmol, The Radiochemical 
Centre, Amersham, Buckinghamshire, England) in 
20 ~tl of saline was added to each culture. The cultures 
were harvested in a multiple-sample processor [23] 
and the radioactivity incorporated into DNA was 
measured in a liquid scintillation spectrometer. Quench- 
ing, estimated by the external standard method, was 
very similar throughout each experiment and therefore 
results were expressed as counts per min. 
The lymphocyte response to PHA was found to be 
lower in cultures containing serum rich in PZ protein 
than in cultures poor in this protein (fig. 1). 
The lymphocyte response to PHA was lower in the 
presence of PZ protein than in the saline and albumin 
controls (fig. 2). 
4. Discussion 
The pregnancy zone protein has been found in in- 
creased amounts not only in pregnant women, but 
also in women taking oral contraceptive drugs [14, 
24-26] and in men treated with oestrogen for pros- 
tatic cancer [13,27]. The hypothesis that PZ might 
function as a steroid carrier has not been supported 
by recent experimental evidence [28, 29]. The obser- 
vation in this investigation that the PZ protein inhibits 
the PHA stimulation of lymphocytes raises the ques- 
tion whether this protein may function as an immuno- 
suppressor during pregnancy. 
Since the first report of the pregnancy zone protein 
[8] there have been several investigations on various 
a2-globulins with characteristics more or less similar 
to those of PZ. Whether Xh [30], SP 3 [31], a-Pregno- 
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globulin [32] and the pregnancy associated globulin 
(PAG-Pal) [33] represent the same protein as PZ is 
not clear. Stimson [34] recently described the purifi- 
cation of an a2-glycoprotein from pregnancy serum 
with a tool. wt. of 506 000. Home et al [35] were un- 
able to demonstrate a depressive effect on the re- 
sponse of lymphocytes to PHA and PPD of  sera con- 
taining measurable quantities of PAG. 
The mechanism behind the effect of PZ on the 
lymphocyte response to PHA is unknown. One possi- 
bility is that the pregnancy zone protein binds to the 
lymphocytes, thereby preventing the reaction between 
PHA and the lymphocytes. Another possibility is that 
PHA reacts with and becomes inactivated by the preg- 
nancy zone protein. 
The effect of  PZ on the lumphocyte response to 
PHA may be related to the finding by Kasakura [7] of 
immunosuppressive properties of pregnancy serum. 
This inhibitory activity was more pronounced in preg- 
nancy seruha of longer gestation time, reached a maxi- 
mum at the time of delivery, and then disappeared 
rapidly during the puerperium. The results presented 
in fig. 1 with the difference between sera high and low 
in PZ concentration also reflect the difference between 
sera from late and early pregnancy. 
Another observation of interest in this context is 
the recently reported epressed lymphocyte response 
in women taking oral contraceptives [36]. 
Various homologous glycoproteins are known to 
inhibit the PHA-induced lymphocyte stimulation. 
However, none of these glycoproteins seems to be 
identical with PZ. The immunoregularatory alpha glob- 
ulin described by Cooperband et al. [37] occurs in 
non-pregnant healthy subjects, a.nd can be distinguished 
by electrophoresis from PZ. A placental glycoprotein 
[38] and a factor in amniotic fluid [39] both depress 
the lymphocyte response to PHA but differ from PZ 
which is not found in cord blood, nor in amniotic 
fluid. 
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